Leerink Partnrs Research Analysts Increase Earnings Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at Leerink Partnrs upped their FY2026 earnings per share estimates for Madrigal Pharmaceuticals in a note issued to investors on Wednesday, August 7th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings per share of $2.10 for the year, up from their prior forecast of $1.96. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($27.70) per share. Leerink Partnrs also issued estimates for Madrigal Pharmaceuticals’ FY2027 earnings at $22.76 EPS and FY2028 earnings at $38.44 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($7.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.55) by $0.45. The company had revenue of $14.64 million for the quarter, compared to the consensus estimate of $4.25 million. The firm’s quarterly revenue was up 146280.0% compared to the same quarter last year. During the same period last year, the business posted ($4.69) earnings per share.

Other equities research analysts have also recently issued research reports about the stock. JMP Securities increased their price target on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a “market outperform” rating in a research report on Tuesday, July 16th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, July 23rd. Wolfe Research began coverage on shares of Madrigal Pharmaceuticals in a research report on Tuesday, June 11th. They set an “outperform” rating and a $382.00 price objective on the stock. Citigroup dropped their target price on shares of Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating for the company in a research report on Thursday. Finally, StockNews.com upgraded shares of Madrigal Pharmaceuticals to a “sell” rating in a research report on Friday, July 19th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $343.83.

Madrigal Pharmaceuticals Trading Down 1.6 %

MDGL stock traded down $3.84 during midday trading on Friday, hitting $239.80. The company had a trading volume of 156,464 shares, compared to its average volume of 481,451. The stock has a market cap of $5.11 billion, a price-to-earnings ratio of -10.55 and a beta of -0.42. Madrigal Pharmaceuticals has a 52 week low of $119.76 and a 52 week high of $299.98. The company has a current ratio of 9.39, a quick ratio of 9.39 and a debt-to-equity ratio of 0.14. The stock’s 50 day moving average price is $272.30 and its 200 day moving average price is $245.85.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MDGL. Envestnet Asset Management Inc. increased its stake in shares of Madrigal Pharmaceuticals by 198.8% in the second quarter. Envestnet Asset Management Inc. now owns 14,454 shares of the biopharmaceutical company’s stock worth $4,049,000 after purchasing an additional 9,616 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $414,000. American Century Companies Inc. grew its position in Madrigal Pharmaceuticals by 13.7% in the second quarter. American Century Companies Inc. now owns 111,113 shares of the biopharmaceutical company’s stock worth $31,130,000 after acquiring an additional 13,361 shares in the last quarter. Dorsey & Whitney Trust CO LLC bought a new stake in Madrigal Pharmaceuticals during the second quarter worth approximately $262,000. Finally, Quest Partners LLC raised its position in Madrigal Pharmaceuticals by 5,225.0% during the second quarter. Quest Partners LLC now owns 213 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 209 shares during the period. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Madrigal Pharmaceuticals

In other news, VP Robert E. Waltermire sold 1,036 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $231.34, for a total transaction of $239,668.24. Following the completion of the transaction, the vice president now directly owns 5,500 shares in the company, valued at $1,272,370. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Robert E. Waltermire sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $285.00, for a total value of $570,000.00. Following the sale, the vice president now owns 5,500 shares in the company, valued at $1,567,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert E. Waltermire sold 1,036 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $231.34, for a total transaction of $239,668.24. Following the sale, the vice president now owns 5,500 shares of the company’s stock, valued at $1,272,370. The disclosure for this sale can be found here. Insiders sold a total of 27,425 shares of company stock valued at $6,129,127 in the last 90 days. Corporate insiders own 23.92% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.